A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bladder (OAB).

Trial Profile

A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bladder (OAB).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs XEN D0501 (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Xention
  • Most Recent Events

    • 16 Nov 2011 Planned number of patients changed from 180 to 300 as reported by European Clinical Trials Database.
    • 13 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top